Healthcare -
Biotechnology - NASDAQ - US
$ 0.7804
1.63 %
$ 25.8 M
Market Cap
-7.53
P/E
1. INTRINSIC VALUE
Balance Sheet
Jupiter Neurosciences, Inc.
| Current Assets | 4.65 M |
| Cash & Short-Term Investments | 3.77 M |
| Receivables | 0 |
| Other Current Assets | 881 K |
| Non-Current Assets | 1.55 M |
| Long-Term Investments | 0 |
| PP&E | 69.6 K |
| Other Non-Current Assets | 1.48 M |
| Current Liabilities | 2.01 M |
| Accounts Payable | 279 K |
| Short-Term Debt | 197 K |
| Other Current Liabilities | 1.53 M |
| Non-Current Liabilities | 21.2 K |
| Long-Term Debt | 21.2 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Jupiter Neurosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 3.09 M |
| Operating Income | -3.09 M |
| Other Expenses | -652 K |
| Net Income | -2.44 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Jupiter Neurosciences, Inc.
| Net Income | -2.44 M |
| Depreciation & Amortization | 43.3 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.84 M |
| Change in Working Capital | -2.57 M |
| Others | -3.16 M |
| Free Cash Flow | -3.91 M |
Wall Street Analysts Price Targets
Jupiter Neurosciences, Inc.
JUNS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
JUNS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Jupiter Neurosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today issued a statement regarding recent market volatility and highlighted its planned Direct-to-Consumer product launch later this year, which is expected to generate near-term revenues while the Company advances its clinical trials.
globenewswire.com
- 4 months ago
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC ("Zina") to support all aspects of Jupiter's upcoming Phase 2a clinical trial for Parkinson's disease.
globenewswire.com
- 4 months ago
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the closing of its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share for gross proceeds of $11 million, before deducting underwriting discounts and other related expenses.
globenewswire.com
- 6 months ago
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the pricing of its initial public offering (the “Offering”) of 2,750,000 shares of common stock at a price of $4.00 per share.
globenewswire.com
- 6 months ago
8. Profile
Summary
Jupiter Neurosciences, Inc. JUNS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 25.8 M
Dividend Yield
0.00%
Description
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Contact
1001 North US HWY 1, Jupiter, FL, 33477
https://www.jupiterorphan.com
IPO
Date
Jan. 18, 2022
Employees
4
Officers
Dr. Claes Wahlestedt M.D., Ph.D.
Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
Dr. Shaun P. Brothers Ph.D.
Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research
Ms. Alison D. Silva MA, MS
President, Chief Business Officer & Director
Dr. Marshall Hayward Ph.D.
Co-Founder, Chief Scientific Officer & Director
Mr. Saleem Elmasri CPA
Chief Financial Officer & Secretary
Mr. Christer Rosen
Co-Founder, Chief Executive Officer & Chairman of the Board
Mr. Alexander Rosen
Co-Founder & Chief Administrative Officer